Ewing Sarcoma Clinical Trials

22 studies are recruiting for ewing sarcoma in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

   Substudy 01A is part of a platform study. The purpose of this study is to assess the efficacy and safety of zilovertamab vedotin in pediatric participants with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), diffuse large B-cell lymphoma (DLBCL)/Burkitt lymphoma, or neuroblastom…

   Stage

   Phase 1

   Ages

   0 to 25

   Site

   Children's Hospital Los Angeles ( Site 1006), Los Angeles, California

   Locations

   71 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT06395103 on ClinicalTrials.gov

2. Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas

   This is a first-in-human, open-label, non-randomized, three-part phase 1 trial of INBRX-109, which is a recombinant humanized tetravalent antibody targeting the human death receptor 5 (DR5).

   Stage

   Phase 1

   Ages

   12 to 85

   Site

   Precision NextGen Oncology and Research, Beverly Hills, California

   Locations

   37 in total

   Run by

   Inhibrx Biosciences, Inc

   See if you can join NCT03715933 on ClinicalTrials.gov

3. Cabozantinib With Ifosfamide in Relapsed/Refractory Sarcomas

   The purpose of this study is to better understand how safe and effective the drug cabozantinib in combination with high-dose ifosfamide is in the treatment of children and adults with relapsed/refractory sarcomas.

   Stage

   Phase 1

   Ages

   5 to 40

   Site

   University of California San Francisco, San Francisco, California

   Locations

   4 in total

   Run by

   Children's Hospital of Philadelphia

   See if you can join NCT06156410 on ClinicalTrials.gov

4. Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas

   The purpose of this study is to evaluate the investigational oral drug AMXT 1501 in combination with oral eflornithine (DFMO). An investigational drug is one that has not been approved by the U.S. Food \& Drug Administration (FDA), or any other regulatory authorities around the world for use alone …

   Stage

   Phase 1

   Ages

   Up to 26

   Site

   University of Alabama/Children's of Alabama, Birmingham, Alabama

   Locations

   14 in total

   Run by

   Milton S. Hershey Medical Center

   See if you can join NCT06465199 on ClinicalTrials.gov

5. Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors

   The purpose of this study is to evaluate the investigational drug, silmitasertib (a pill taken by mouth), in combination with FDA approved drugs for solid tumors. An investigational drug is one that has not been approved by the U.S. Food \& Drug Administration (FDA), or any other regulatory authori…

   Stage

   Phase 1

   Ages

   Up to 30

   Site

   University of Alabama/Children's of Alabama, Birmingham, Alabama

   Locations

   23 in total

   Run by

   Milton S. Hershey Medical Center

   See if you can join NCT06541262 on ClinicalTrials.gov

6. Lurbinectedin in FET-Fused Tumors

   The purpose of this study is to find out if a drug called lurbinectedin (the "study drug") is safe and effective at treating people with recurrent or relapsed solid tumors, including Ewing sarcoma.

   Stage

   Phase 1

   Ages

   10 and older

   Site

   Cedars-Sinai Medical Center, Los Angeles, California

   Locations

   6 in total

   Run by

   Children's Hospital of Philadelphia

   See if you can join NCT05918640 on ClinicalTrials.gov

7. Evaluation of Xaluritamig in Adults, Adolescents and Children With Relapsed or Refractory Ewing Sarcoma (EWS)

   The main objectives of this trial are to determine the recommended dose for expansion of xaluritamig (dose confirmation part only) and to determine the safety and tolerability of xaluritamig in adult, adolescent and pediatric participants with relapsed or refractory EWS.

   Stage

   Phase 1

   Ages

   2 and older

   Site

   Cedars Sinai Medical Center, Los Angeles, California

   Locations

   9 in total

   Run by

   Amgen

   See if you can join NCT07297979 on ClinicalTrials.gov

8. Integration of Adaptive Proton Therapy in Pediatric Solid Tumors and Hodgkin's Lymphoma

   Pediatric patients receiving proton therapy for solid tumors or Hodgkin's lymphoma may experience anatomical changes during treatment that can affect proton therapy accuracy. This prospective single-arm study uses regular low-dose imaging to monitor these changes and adjust treatment plans as neede…

   Stage

   Not phased

   Ages

   Any age

   Site

   St. Jude Children's Research Hospital, Memphis, Tennessee

   Run by

   St. Jude Children's Research Hospital

   See if you can join NCT07514819 on ClinicalTrials.gov

9. Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)

   This is a phase I dose-escalation study to determine the safety and feasibility of autologous CAR-TA T cells (B7-H3 CAR+ T cells administered with DNR-PRAME Tumor Antigen-specific T cells) following lymphodepleting chemotherapy in participants with relapsed/refractory rhabdomyosarcoma, Ewing sarcom…

   Stage

   Phase 1

   Ages

   1 to 23

   Site

   Children's National Hospital, Washington D.C., District of Columbia

   Locations

   2 in total

   Run by

   Children's National Research Institute

   See if you can join NCT07172958 on ClinicalTrials.gov

10. Feasibility Study on the Effect of a Methionine-Reduced Diet on Serum Levels in Pts w/ Solid Tumors

    This is a pilot clinical trial determining the effect of a Methionine-reduced diet on serum levels in subjects with solid tumors. These are subjects who will receive systemic standard of care cancer therapy.

    Stage

    EARLY_Phase 1

    Ages

    18 and older

    Site

    Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange, California

    Run by

    University of California, Irvine

    See if you can join NCT07628634 on ClinicalTrials.gov

11. Targeted Oligometastatic Radiation in Pediatric and Young Adult Patients With Soft Tissue and Bone Sarcoma

    This study is designed for children, adolescents and young adults undergoing radiation therapy for metastatic sarcoma. The aim of the study is to investigate if the investigators can improve the overall survival of these patients by targeting metastatic sites with radiation.

    Stage

    Not phased

    Ages

    Up to 39

    Site

    Sibley Memorial Hospital, Washington D.C., District of Columbia

    Locations

    3 in total

    Run by

    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

    See if you can join NCT06796543 on ClinicalTrials.gov

12. Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma

    Ewing sarcoma (EWS) and osteosarcoma primarily affect adolescents and young adults. Common treatments include chemotherapy, surgery and radiation, however, there have been few recent advancements in the standard of care. By incorporating eflornithine (DFMO) as an additional therapy and/or maintenan…

    Stage

    Phase 2

    Ages

    0 to 50

    Site

    St. Joseph's Children's Hospital, Tampa, Florida

    Locations

    2 in total

    Run by

    Milton S. Hershey Medical Center

    See if you can join NCT07321912 on ClinicalTrials.gov

13. Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors

    Hematopoietic stem cell transplantation can cure patients with blood cancer and other underlying diseases. αβ-T cell and B cell depletion has been introduced to decrease GVHD and PTLD and has demonstrated effectiveness for hematologic malignancies and non-malignant diseases additionally increasing …

    Stage

    Phase 1

    Ages

    0 to 25

    Site

    University of Florida, Gainesville, Florida

    Run by

    University of Florida

    See if you can join NCT06625190 on ClinicalTrials.gov

14. XL092 (Zanzalintinib) for the Treatment of Patients With Metastatic or Unresectable Leiomyosarcoma, Bone Sarcoma or Translocation-associated Soft Tissue Sarcoma

    This phase II trial tests how well zanzalintinib (XL092) works in treating patients with leiomyosarcoma that has spread from where it first started to other places in the body (metastatic) or that cannot be removed by surgery (unresectable). Leiomyosarcomas are a type sarcoma that can occur in any …

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Northwestern University, Chicago, Illinois

    Run by

    Northwestern University

    See if you can join NCT06571734 on ClinicalTrials.gov

15. Biologically-Adapted, Dose-Escalated Radiotherapy for the Treatment of Ewing Sarcoma, BEAR Trial

    This clinical trial evaluates the effect of radiotherapy doses based on tumor size and tumor-specific characteristics (biologically-adapted) in treating patients with Ewing sarcoma. Radiotherapy uses high energy x-rays, particles, or radioactive seeds to kill tumor cells and shrink tumors. Conventi…

    Stage

    Not phased

    Ages

    2 and older

    Site

    Mayo Clinic in Rochester, Rochester, Minnesota

    Locations

    2 in total

    Run by

    Mayo Clinic

    See if you can join NCT07188532 on ClinicalTrials.gov

16. A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies

    A Phase 1/1B Study of ST-01156 in Patients with Advanced Solid Malignancies

    Stage

    Phase 1

    Ages

    16 and older

    Site

    The City of Hope National Medical Center, Duarte, California

    Locations

    6 in total

    Run by

    SEED Therapeutics, Inc.

    See if you can join NCT07197554 on ClinicalTrials.gov

17. B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)

    3CAR is being done to investigate an immunotherapy for patients with solid tumors. It is a Phase I clinical trial evaluating the use of autologous T cells genetically engineered to express B7-H3-CARs for patients ≤ 21 years old, with relapsed/refractory B7-H3+ solid tumors. This study will evaluate…

    Stage

    Phase 1

    Ages

    Up to 21

    Site

    St. Jude Children's Research Hospital, Memphis, Tennessee

    Run by

    St. Jude Children's Research Hospital

    See if you can join NCT04897321 on ClinicalTrials.gov

18. Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies

    Investigators are testing new experimental drug combinations such as the combination of vorinostat, vincristine, irinotecan, and temozolomide in the hopes of finding a drug that may be effective against tumors that have come back or that have not responded to standard therapy. The goals of this stu…

    Stage

    Phase 1

    Ages

    1 to 30

    Site

    New York Medical College, Valhalla, New York

    Run by

    New York Medical College

    See if you can join NCT04308330 on ClinicalTrials.gov

19. Hypofractionated Radiation in Combination With B7-H3-CAR T Cells for Pediatric Patients With Relapsed/Refractory Sarcomas

    RAD3CAR is a phase I study designed to evaluatethe safety of B7-H3-CAR T cells and lymphodepletion in combination with hypofractionated radiation therapy. Primary objective: - To evaluate the safety of B7-H3-CAR T cell therapy after priming with hypofractionated radiation therapy (HFRT) and lymphod…

    Stage

    Phase 1

    Ages

    Up to 21

    Site

    St. Jude Children's Research Hospital, Memphis, Tennessee

    Run by

    St. Jude Children's Research Hospital

    See if you can join NCT07222735 on ClinicalTrials.gov

20. Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma

    This study is conducted in two phases. The phase 1 portion of the study evaluates the safety, tolerability, pharmacokinetics (PK), recommended phase 2 dose (RP2D), and effectiveness of lurbinectedin monotherapy in pediatric participants with previously treated solid tumors. This is followed by the …

    Stage

    Phase 1

    Ages

    2 to 30

    Site

    Children's Hospital of Los Angeles, Los Angeles, California

    Locations

    15 in total

    Run by

    Jazz Pharmaceuticals

    See if you can join NCT05734066 on ClinicalTrials.gov

21. HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma

    The purpose of this study is to learn whether it is safe to give HER2-CAR T cells in combination with an immune checkpoint inhibitor drug (pembrolizumab or nivolumab), to learn what the side effects are, and to see whether this therapy might help patients with sarcoma. Another goal of this study is…

    Stage

    Phase 1

    Ages

    1 to 25

    Site

    Texas Children's Hospital, Houston, Texas

    Run by

    Baylor College of Medicine

    See if you can join NCT04995003 on ClinicalTrials.gov

22. Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors

    This phase I trial studies the safety of transplantation with a haploidentical donor peripheral blood stem cell graft depleted of TCRαβ+ cells and CD19+ cells in conjunction with the immunomodulating drug, Zoledronate, given in the post-transplant period to treat pediatric patients with relapsed or…

    Stage

    Phase 1

    Ages

    0 to 21

    Site

    University of Wisconsin Carbone Cancer Center, Madison, Wisconsin

    Run by

    University of Wisconsin, Madison

    See if you can join NCT02508038 on ClinicalTrials.gov